Why Is Alkermes (ALKS) Down 2.6% Since Last Earnings Report?

Core Viewpoint - Alkermes reported mixed financial results for Q4 2025, with adjusted earnings beating estimates but total revenues declining year-over-year, raising questions about future performance and investor sentiment [2][3][12]. Financial Performance - Adjusted earnings from continuing operations were 46 cents per share, surpassing the Zacks Consensus Estimate of 43 cents, but down from $1.04 per share in the same quarter last year [2]. - Total revenues for Q4 2025 were $384.5 million, a decrease of 10.6% from the previous year, yet still exceeding the Zacks Consensus Estimate of $380 million [3]. Product Sales - Sales from proprietary products grew 2.5% year-over-year to $315.5 million, driven by strong demand for Lybalvi, aligning with management's guidance of $300-$320 million [5]. - Vivitrol sales decreased by 7.5% year-over-year to $124.1 million, while Aristada sales increased by 0.6% to $97.2 million, both exceeding their respective consensus estimates [5][6]. - Lybalvi generated sales of $94.1 million, up 22.2% year-over-year, with total prescriptions growing by 25% [6]. Revenue Breakdown - Manufacturing and royalty revenues fell approximately 43.4% year-over-year to $69.1 million, with specific contributions from Biogen's Vumerity and other products [6][7]. - Research and development expenses rose by 59.8% year-over-year to $93 million, primarily due to ongoing studies on alixorexton [7]. Cash Position - As of December 31, 2025, Alkermes had cash and cash equivalents of $1.32 billion, an increase from $1.14 billion on September 30, 2025 [8]. 2026 Guidance - The company anticipates total revenues between $1.73 billion and $1.84 billion for 2026, driven mainly by net sales of proprietary products expected to be in the range of $1.52 billion to $1.60 billion [9]. - Specific product sales forecasts include Vivitrol at $460-$480 million, Aristada at $365-$385 million, and Lybalvi at $380-$400 million, with newly acquired Lumryz expected to generate $315-$335 million [10]. Expense Projections - Research and development expenses are projected to be between $445 million and $485 million, while selling, general, and administrative expenses are expected to range from $890 million to $930 million [11]. Market Sentiment - There has been a downward trend in estimates revisions over the past two months, indicating a cautious outlook among investors [12]. - Alkermes currently holds a Zacks Rank 5 (Strong Sell), suggesting expectations of below-average returns in the near term [14].